Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
Business Wire•29/07/2026•17:28 ET
0
Whiz Insights
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
* Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease
Get started
Create a free account to read the full story.